Vera Therapeutics Inc Stock Price Today - Investing.com

View today's Vera Therapeutics Inc stock price and latest VERA news and analysis. Create real-time notifications to follow any changes in the live stock price. ... Investing.com; Jan 10, 2025;

$35
OFF

VERA Stock Price | Vera Therapeutics Inc. Stock Quote (U.S.: …

1 week from now

Jan 6, 2025 · Vera Therapeutics started at overweight with $35 stock price target at J.P. Morgan Jul. 12, 2022 at 6:48 a.m. ET by Tomi Kilgore Vera Therapeutics started at outperform with …

marketwatch.com

3%
OFF

What's Going On With Vera Therapeutics Stock? - Benzinga

1 week from now

4 days ago · Vera Therapeutics Inc VERA shares are trading lower by 7.3% to $34.31 Monday afternoon. The company announced an exclusive license agreement with Stanford University …

benzinga.com

$75.00
OFF

Evercore ISI Sticks To Its Buy Rating For Vera Therapeutics (VERA)

1 week from now

3 days ago · Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $75.00. The company’s shares …

businessinsider.com

25%
OFF

Vera Therapeutics Grants Stock Options And RSUs To Six New

1 week from now

The stock options have an exercise price of $42.19 per share, which was the closing price on January 8, 2025. The options will vest over four years, with 25% of the shares vesting on the …

nasdaq.com

$139.57
OFF

TScan Therapeutics' SWOT Analysis: Innovative T-cell Therapy Stock ...

1 week from now

1 day ago · TScan Therapeutics Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company with a market capitalization of $139.57 million, is poised at a critical juncture in its …

investing.com

$43800
OFF

Vyne Therapeutics Director Patrick Lepore Buys $43,800 In Stock

1 week from now

1 day ago · Patrick G. LePore, a director at VYNE Therapeutics Inc. (NASDAQ:VYNE), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on …

investing.com

$6.66
OFF

Revance Therapeutics: The Takeover Saga Continues As Teoxane …

1 week from now

3 days ago · Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. …

seekingalpha.com

FAQs about Vera Therapeutics Inc Stock Price Today - Investing.com Coupon?

Where is Vera Therapeutics Inc headquartered?

The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA. VERA | Complete Vera Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ...

Should you buy Vera Therapeutics (Vera)?

Currently, the analyst consensus on Vera Therapeutics is a Strong Buy with an average price target of $68.00. VERA market cap is currently $2.34B and has a P/E ratio of -13.38. TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. ...

Who is Vera Therapeutics?

Visit a quote page and your recently viewed tickers will be displayed here. Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA. ...

Is Vera Therapeutics planning a $65 million IPO?

Vera Therapeutics is planning a $65 million IPO. The firm is advancing treatment programs for IgAN and Lupus Nephritis, two kidney diseases. Vera Therapeutics seeks to make progress on atacicept, which it in-licensed from Merck and early results have been positive, so the IPO is worth consideration. ...

Does Vera Therapeutics offer inducement Awards?

BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting of ... ...

What is Vera's new approach to B cell modulation?

“This novel approach is part of Vera’s broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we treat patients suffering from a variety of B cell mediated diseases. ...